RxDoctor Payments Data

Michelle Smothers

Family · Memphis, TNNPI 1275800351

Payments from drug & device makers

$581in general payments, 2019–2025

Across 16 payments — averaging $36.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$139
  • Amgen$117
  • AstraZeneca$112
  • Abbott$93
  • Lilly USA, LLC$45
  • Boston Scientific$35
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$139
Amgen1$117
AstraZeneca1$112
Abbott4$93
Lilly USA, LLC3$45
Boston Scientific2$35
Novo Nordisk1$24
Medtronic1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$581 in reported general payments places this provider in the 50th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$60,519
Medicare patients
261
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$28,178
OzempicSemaglutide16$23,950
MounjaroTirzepatide14$15,073
LinzessLinaclotide11$14,190
Tresiba Flextouch U-200Insulin Degludec12$11,403
Atorvastatin Calcium167$1,926
Albuterol Sulfate HfaAlbuterol Sulfate64$1,905
Rosuvastatin Calcium90$1,793
Losartan Potassium100$1,217
Metoprolol Succinate55$1,016
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12$997
Amlodipine Besylate170$893
SynthroidLevothyroxine Sodium11$877
Bupropion XlBupropion Hcl23$791
Montelukast Sodium72$771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$24$23,95016 claims
Lilly USA, LLCMounjaro$45$15,07314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,706 family providers in Tennessee.

Other family in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →